Asieris (亚虹医药)

Asieris Pharmaceuticals is an innovative drug company focused on genitourinary tumors and women's health, with a stated mission to improve human health and preserve patients' dignity. Its marketed and pipeline products include Vesique (APL-1202) and Cevira (APL-1702), spanning urologic oncology, women's health, and breast and gynecologic oncology through in-house R&D and licensing. Technology platforms include Targeted Immunomodulator Normalization (TIMN), Prodrugs Accurate Drug Delivery (TAIDD), and fragment-based DDC chimeras. Recent milestones include FDA IND approval for a CLDN6/9 ADC for advanced solid tumors and China marketing approval for a blue-light cystoscopy system for bladder cancer.